Education
About Us
Working with TipRanks
Follow Us
Talphera (TLPH)
NASDAQ:TLPH
TLPH Stock Chart & Stats
Day’s Range― - ―
52-Week Range$0.50 - $1.27
Previous CloseN/A
Volume42.81K
Average Volume (3M)41.62K
Market Cap
$10.90M
Enterprise Value$17.86M
Total Cash (Recent Filing)$87.97M
Total Debt (Recent Filing)$105.67M
Price to Earnings (P/E)―
Beta1.30
Next Earnings
May 19, 2025EPS Estimate
-0.17Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.68
Shares Outstanding17,029,219
10 Day Avg. Volume28,530
30 Day Avg. Volume41,623
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)38.46
Price to Cash Flow (P/CF)-0.90
P/FCF Ratio0.00
Enterprise Value/Market Cap1.64
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-3.65
Enterprise Value/Ebitda-1.18
Forecast
1Y Price Target
$5.00Price Target Upside706.45% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
---
Talphera News
PremiumCompany Announcements
Talphera Reports Q3 2024 Results and Study Progress
PremiumCompany Announcements
Talphera Announces CMO Retirement and Successor Appointment---
Bulls Say, Bears Say
Bulls Say
Clinical EnrollmentTalphera is expanding the number of clinical sites to 14, from 10, to help expedite the study.
Drug AdvantagesNafamostat, Niyad's active drug component, is approved in Japan and South Korea as a regional anticoagulant for the dialysis circuit, disseminated intravascular coagulation, and acute pancreatitis, with over 30 years of real-world evidence.
Regulatory ProgressThe FDA agreed to review the PAS submission within 30 days of its submission to enable formal amendments to the study protocol.
Bears Say
Guidance UncertaintyTalphera has not given guidance of when enrollment may be completed and data readouts provided.
Trial RisksKey risks to the rating and price target include failed or equivocal trial results and failure to secure FDA approval for Niyad.
---
Ownership Overview
13.59% Insiders
2.30% Mutual Funds
19.47% Other Institutional Investors
63.22% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
TLPH FAQ
What was Talphera’s price range in the past 12 months?
Talphera lowest stock price was $0.50 and its highest was $1.27 in the past 12 months.
What is Talphera’s market cap?
Talphera’s market cap is $10.90M.
When is Talphera’s upcoming earnings report date?
Talphera’s upcoming earnings report date is May 19, 2025 which is in 52 days.
How were Talphera’s earnings last quarter?
Talphera released its earnings results on Nov 13, 2024. The company reported -$0.13 earnings per share for the quarter, beating the consensus estimate of -$0.19 by $0.06.
Is Talphera overvalued?
According to Wall Street analysts Talphera’s price is currently Undervalued.
Does Talphera pay dividends?
Talphera does not currently pay dividends.
What is Talphera’s EPS estimate?
Talphera’s EPS estimate is -0.17.
How many shares outstanding does Talphera have?
Talphera has 17,029,219 shares outstanding.
What happened to Talphera’s price movement after its last earnings report?
Talphera reported an EPS of -$0.13 in its last earnings report, beating expectations of -$0.19. Following the earnings report the stock price went down -25.843%.
Which hedge fund is a major shareholder of Talphera?
Currently, no hedge funds are holding shares in TLPH
---
Company Description
Talphera
Talphera, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for use in medically supervised settings. Its lead product candidate is Niyad, a lyophilized formulation of nafamostat, which is under an investigational device exemption as an anticoagulant for the extracorporeal circuit. It is also developing LTX-608, an anti-inflammatory and antiviral potential for the treatment of multiple conditions, including COVID-19, disseminated intravascular coagulation (DIC), acute respiratory distress syndrome (ARDS), and acute pancreatitis; Fedsyra, a pre-filled ephedrine syringe; and PFS-02, a pre-filled phenylephrine syringe. The company was formerly known as AcelRx Pharmaceuticals, Inc. and changed its name to Talphera, Inc. in January 2024. Talphera, Inc. was incorporated in 2005 and is headquartered in San Mateo, California.
---
TLPH Earnings Call
Q3 2024
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call revealed positive progress in clinical trials, regulatory advantages, and strong investor support, but also highlighted challenges in patient enrollment and financial constraints that require additional capital.Read More>---
TLPH Stock 12 Month Forecast
Average Price Target
$5.00
▲(706.45% Upside)
Technical Analysis
Galectin Therapeutics
―
Neuronetics
―
Anixa Biosciences
―
Rhythm Pharmaceuticals
―
Alnylam Pharma
―
Best Analysts Covering TLPH
1 Year
1 Year Success Rate
5/14 ratings generated profit
1 Year Average Return
-9.49%
reiterated a buy rating 2 months ago
Copying Ed Arce's trades and holding each position for 1 Year would result in 35.71% of your transactions generating a profit, with an average return of -9.49% per trade.
---